$53,000* for Development of a Pharmacodynamic Marker of EWS-FLII Activity to Aid in the Clinical Translation of Targeted Therapies for Ewings Sarcoma
Vanderbilt University; Patrick J. Grohar, M.D., PhD
Research for a new therapy that targets the dominant oncogene of Ewing Sarcoma, EWS-FLI1, to improve survival rates.
$53,000* for Development of a Novel Mer TKI for Treatment of ALL
Dr. Doug Graham - University of Colorado, Denver
Research of treatment for acute lymphoblastic leukemia (ALL) by targeting Mer signals (which have been shown to contribute to ALL) with biological agent UNC2025.
$53,000* for Treatment of Medulloblastoma
Margarita Gutova, M.D. - Beckman Research Institute of City of Hope
Research for a more effective treatment for medulloblastoma (MB), using neural stem cells that produce anti-cancer drugs localized directly to MB cells to limit toxicity.
$53,000* for Engineering the Lymph Node Environment with Therapeutic Vaccine Depots to Combat Neuroblastoma
Christopher M. Jewell, PhD - University of Maryland, College Park;
Research combining direct lymph node delivery and vaccines to generate immune responses to combat neuroblastoma.